Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2016, Vol. 43 Issue (5): 631-637    DOI: 10.12891/ceog3005.2016
Review | Next articles
The feasibility of establishing classification system for ovarian function
Wei Wang1, Yan-Qing Wang1, Ying-Ying Qin2, Yu-Jie Dang2, Ming-Di Xia2, Ying Ma3, Yu-Lan Mu4, *()
1Department of Ultrasonic Diagnosis & Treatment, Shandong Provincial Hospital Affiliated to Shandong University, Jinan
2Reproductive Hospital Affiliated to Shandong University, Jinan
3Medical College of Qingdao University, Qingdao
4Department of Obstetrics & Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan (China)
Download:  PDF(87KB)  ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
The occurrence, development, and decline of ovarian function are the foundation in women's whole life stages, which reflect the process beginning from embryo formation to the aging. Correct assessment of ovarian function is significant for evaluating the potential reproductive ability and predicting the age of menopause, as well as providing both individualized and proper treatment and preventive care based on physiological characteristics of women in different phases. Ovarian reserve (OR) is used to predict the potential fertility of women by evaluating the follicles and the quantity and quality of eggs. Currently, there are multiple indexes used to evaluate ovarian reserve, including anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), estradiol (E2), inhibin B, antral follicle count (AFC), etc. Although some scholars combine multiple indexes to evaluate the ovarian function, these indexes are far less accurate, detailed, and comprehensive. To find an ideal method for evaluation of ovarian reserve is the hotspot in research of reproductive endocrine. The present authors, for the first time, put forward a classification system of ovarian reserve function after summarizing numerous cases. It can both accurately and effectively evaluate the ovarian function quantitatively. It is of great help in making clinical decisions and of great significance in future development.
Key words:  Ovarian reserve      Anti-Müllerian hormone (AMH)      Inhibin B (INH B)      Antral follicle count (AFC)      Follicle stimulating hormone      Estradiol     
Published:  10 October 2016     
*Corresponding Author(s):  YU-LAN MU     E-mail:  mulanxing@hotmail.com

Cite this article: 

Wei Wang, Yan-Qing Wang, Ying-Ying Qin, Yu-Jie Dang, Ming-Di Xia, Ying Ma, Yu-Lan Mu. The feasibility of establishing classification system for ovarian function. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(5): 631-637.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3005.2016     OR     https://ceog.imrpress.com/EN/Y2016/V43/I5/631

[1] Yu Deng, Zhan-Hui Ou, Min-Na Yin, Pei-Ling Liang, Zhi-Heng Chen, Abraham Morse, Ling Sun. Age and anti-Műllerian hormone: prediction of cumulative pregnancy outcome in in vitro fertilization with diminished ovarian reserve[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 835-841.
[2] Aybike Pekin, Ayşe Gül Kebapçılar, Ersin Çintesun, Setenay Arzu Yılmaz, Özlem Seçilmiş Kerimoğlu. Comparison of an estradiol patch and GnRH-antagonist protocol with a letrozole/antagonist protocol for patients without oocyte development, fertilization and/or embryo development in previous IVF cycles[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 924-928.
[3] Engin Turkgeldi, Sule Yildiz, Berk Angun, Bulent Urman, Baris Ata. Oocyte yield of GnRH antagonist cycles scheduled with a short course of estradiol in the early follicular phase[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 278-282.
[4] I. Thanaboonyawat, P. Chera-aree, S. Petyim, R. Choavaratana, P. Laokirkkiat. The effect of three-month topical testosterone gel application on semen quality in men with oligozoospermia and low serum testosterone levels[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 875-881.
[5] H. Saleh, F. Moiety, A.F. Agameya, Y. Elkassar, R.M. El Sharakwy, D. Zeidan, H. Elmeligy. Comparison between antral follicle count and anti-Müllerian hormonal level in the prediction of ovarian response and pregnancy outcome in intracytoplasmic sperm injection patients: implications in personalizing ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 166-173.
[6] E. Kadour-Peero, S. Khoury, J. Awad, L. Shpritz, L. Chen-Konak, C. Shechner, L. Saiegh. Determination of estradiol and progesterone concentrations in human scalp hair[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 268-271.
[7] Hue HJ, Kim SK, Choi JY, Suh DH, Kim KD, No JH, Lee JR, Jee BC, Kim YB, Jeon HW. Previous ovarian surgery increases the risk of tubal factor infertility[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 84-88.
[8] P. Bakas, M. Simopoulou, P. Panagopoulos, N. Salakos, Ch. Siristatidis. Luteal phase progesterone and estradiol concentrations and their relation to the outcome of IVF/ICSI cycles with controlled ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 727-730.
[9] N. Eamudomkarn, L. Salang, K. Seejorn, P. Kleebkaow. Comparison of impact on ovarian reserve between laparoscopic and laparotomy ovarian cystectomy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 779-783.
[10] L.-S. Wang, X.-L. Zhao, X.-A. Cai, G.-F. Fu. Age specific reference intervals of serum anti-Müllerian hormone concentration of 1,253 women with healthy females in infertility center[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 526-530.
[11] A.H. Kaya, E. Tekgunduz, S. Akpınar, G. Bozdağ, T.N. Yiğenoğlu, A. Merdin, S. Namdaroglu, O. Kayıkcı, F. Altuntaş. Assessment of ovarian reserve with anti-Mullerian hormone in women following allogeneic hematopoietic cell transplantation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 127-130.
[12] L.E. Prado Correia, B.C. de Almeida, E. Chada Baracat, I. Silva, J.M. Soares Júnior, C.E. Bonduki, M. Abi Haidar. Efficacy and effects of transdermal hormone therapy in postmenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 735-740.
[13] J.H. Check. Intractable severe peri-ovulatory sneezing abrogated by injection of human chorionic gonadotropin[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 781-781.
[14] M.B. Celtemen, P. Telli Celtemen, N. Bozkurt, C. Karakaya, S. Elberg, R.H. Gursoy. Follicular fluid anti-Müllerian hormone, inhibin-A, progesterone, and estradiol level differences in patients under controlled ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 166-169.
[15] H. Takagi, T. Sasagawa, Y. Osaka. Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 312-315.
No Suggested Reading articles found!